Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group

In this series, the largest available, metastatic LGFMS, SEF, and H-LGFMS/SEF showed different courses. Systemic agents have modest efficacy, informing future trials of novel agents for these tumours.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2024-09-01
DOI
https://doi.org/10.1016/j.esmoop.2024.103689
Citations
7
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.93

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group

Andrea Napolitano, Andrew J. Wagner, Jonathan C. Trent, Alexander T.J. Lee et al.
7 citations
ESMO Open
Sarcoma Diagnosis and Treatment
2.93
article

Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group

Andrea Napolitano, Andrew J. Wagner, Jonathan C. Trent, Alexander T.J. Lee, Daniel Wong, Carlo María Cicala, Daniel Baumhoer, Ryan A. Denu, Silva Ljevar, Angelo Paolo Dei Tos, Hanna Koseła-Paterczyk, William D. Tap, Vladimir Andelkovic, Herbert H. Loong, Abdulazeez Salawu, Elizabeth A. Connolly, A. Hong, Elizabeth G. Demicco, Rosalba Miceli, Evan Rosenbaum, Robin L. Jones, Alexander J. Lazar, Christopher D.�M. Fletcher, Silvia Stacchiotti, Stefano Taverna, Koichi Ogura, Claudia Giani, Giacomo Giulio Baldi, Alessandro Gronchi, Robert G. Maki, Marta Sbaraglia, Emanuela Palmerini, Antonella Brunello, Judith V.M.G. Bovée, Inga‐Marie Schaefer, Jyoti Bajpai, Zhi Li, Fernando Augusto Batista Campos
article en
7 citations

Abstract

In this series, the largest available, metastatic LGFMS, SEF, and H-LGFMS/SEF showed different courses. Systemic agents have modest efficacy, informing future trials of novel agents for these tumours.

ESMO OpenVol. 9(9)
Brigham and Women's Hospital (US), Mount Sinai Hospital (CA), The University of Sydney (AU), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), National Taiwan University (TW), Chinese University of Hong Kong (HK), University of Toronto (CA), Homi Bhabha National Institute (IN), Leiden University Medical Center (NL), Princess Alexandra Hospital (AU), Sir Charles Gairdner Hospital (AU), University Hospital of Basel (CH), Princess Margaret Cancer Centre (CA), AC Camargo Hospital (BR), Istituto Oncologico Veneto (IT), Prince of Wales Hospital (CN), Dana-Farber Cancer Institute (US), Royal Marsden Hospital (GB), Istituto Ortopedico Rizzoli (IT), Vall d'Hebron Hospital Universitari (ES), The Christie NHS Foundation Trust (GB), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Sylvester Comprehensive Cancer Center (US), Hospital of Prato (IT), Vall d'Hebron Institute of Oncology (ES), University of Pennsylvania (US)
Ministero della Salute
Partnerships for the goals
Openalex Percentile: Top 8%
Sarcoma Diagnosis and Treatment
2.93
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.